Last reviewed · How we verify
Polihexanide 2% — Competitive Intelligence Brief
phase 3
Antiseptic/Antimicrobial agent
Infectious Disease / Wound Care
Small molecule
Live · refreshed every 30 min
Target snapshot
Polihexanide 2% (Polihexanide 2%) — University of Sao Paulo. Polihexanide is a broad-spectrum antimicrobial agent that disrupts bacterial and fungal cell membranes through electrostatic interactions.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Polihexanide 2% TARGET | Polihexanide 2% | University of Sao Paulo | phase 3 | Antiseptic/Antimicrobial agent | ||
| Irrigation with PVI | Irrigation with PVI | The University of Texas Health Science Center, Houston | marketed | Antiseptic/Antimicrobial agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antiseptic/Antimicrobial agent class)
- The University of Texas Health Science Center, Houston · 1 drug in this class
- University of Sao Paulo · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Polihexanide 2% CI watch — RSS
- Polihexanide 2% CI watch — Atom
- Polihexanide 2% CI watch — JSON
- Polihexanide 2% alone — RSS
- Whole Antiseptic/Antimicrobial agent class — RSS
Cite this brief
Drug Landscape (2026). Polihexanide 2% — Competitive Intelligence Brief. https://druglandscape.com/ci/polihexanide-2. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab